The latest price target for Vanda Pharma (NASDAQ:VNDA) was reported by HC Wainwright & Co. on January 28, 2025. The analyst firm set a price target for $18.00 expecting VNDA to rise to within 12 months (a possible 295.17% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Vanda Pharma (NASDAQ:VNDA) was provided by HC Wainwright & Co., and Vanda Pharma reiterated their buy rating.

There is no last upgrade for Vanda Pharma

The last downgrade for Vanda Pharmaceuticals Inc happened on February 25, 2022 when Jefferies changed their price target from $24 to $12 for Vanda Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vanda Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vanda Pharma was filed on January 28, 2025 so you should expect the next rating to be made available sometime around January 28, 2026.

While ratings are subjective and will change, the latest Vanda Pharma (VNDA) rating was a reiterated with a price target of $18.00 to $18.00. The current price Vanda Pharma (VNDA) is trading at is $4.56, which is out of the analyst’s predicted range.